BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG, Gessi S. A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. Med Res Rev 2018;38:1031-72. [PMID: 28682469 DOI: 10.1002/med.21456] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 13.4] [Reference Citation Analysis]
Number Citing Articles
1 Magni G, Ceruti S. Adenosine Signaling in Autoimmune Disorders. Pharmaceuticals (Basel) 2020;13:E260. [PMID: 32971792 DOI: 10.3390/ph13090260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wang JN, Fan H, Song JT. Targeting purinergic receptors to attenuate inflammation of dry eye. Purinergic Signal 2022. [PMID: 35218451 DOI: 10.1007/s11302-022-09851-9] [Reference Citation Analysis]
3 Suresh RR, Gao ZG, Salmaso V, Chen E, Campbell RG, Poe RB, Liston TE, Jacobson KA. Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species. ACS Med Chem Lett 2022;13:623-31. [PMID: 35450351 DOI: 10.1021/acsmedchemlett.1c00685] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev 2018;98:1591-625. [PMID: 29848236 DOI: 10.1152/physrev.00049.2017] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 51.5] [Reference Citation Analysis]
5 Tosh DK, Salmaso V, Rao H, Bitant A, Fisher CL, Lieberman DI, Vorbrüggen H, Reitman ML, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution. J Med Chem 2020;63:4334-48. [PMID: 32271569 DOI: 10.1021/acs.jmedchem.0c00235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fang Z, Xu S, Xie Y, Yan W. Identification of a prognostic gene signature of colon cancer using integrated bioinformatics analysis. World J Surg Oncol 2021;19:13. [PMID: 33441161 DOI: 10.1186/s12957-020-02116-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Jamwal S, Mittal A, Kumar P, Alhayani DM, Al-Aboudi A. Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors. Curr Pharm Des 2019;25:2892-905. [PMID: 31333104 DOI: 10.2174/1381612825666190716112319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Choi H, Jacobson KA, Yu J, Jeong LS. Design and Synthesis of 2,6-Disubstituted-4'-Selenoadenosine-5'-N,N-Dimethyluronamide Derivatives as Human A3 Adenosine Receptor Antagonists. Pharmaceuticals (Basel) 2021;14:363. [PMID: 33920062 DOI: 10.3390/ph14040363] [Reference Citation Analysis]
9 Burnstock G, Jacobson KA, Christofi FL. Purinergic drug targets for gastrointestinal disorders. Curr Opin Pharmacol 2017;37:131-41. [PMID: 29149731 DOI: 10.1016/j.coph.2017.10.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
10 Choudhury H, Chellappan DK, Sengupta P, Pandey M, Gorain B. Adenosine Receptors in Modulation of Central Nervous System Disorders. Curr Pharm Des 2019;25:2808-27. [PMID: 31309883 DOI: 10.2174/1381612825666190712181955] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
11 Coppi E, Cherchi F, Fusco I, Failli P, Vona A, Dettori I, Gaviano L, Lucarini E, Jacobson KA, Tosh DK, Salvemini D, Ghelardini C, Pedata F, Di Cesare Mannelli L, Pugliese AM. Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. Pain 2019;160:1103-18. [PMID: 31008816 DOI: 10.1097/j.pain.0000000000001488] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
12 Su W, Wei Y, Huang B, Ji J. Identification of Hub Genes and Immune Infiltration in Psoriasis by Bioinformatics Method. Front Genet 2021;12:606065. [PMID: 33613635 DOI: 10.3389/fgene.2021.606065] [Reference Citation Analysis]
13 Federico S, Margiotta E, Moro S, Kachler S, Klotz KN, Spalluto G. Potent and selective A3 adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties. RSC Med Chem 2021;12:254-62. [PMID: 34046614 DOI: 10.1039/d0md00380h] [Reference Citation Analysis]
14 Viganò M, Perucca Orfei C, Ragni E, Colombini A, de Girolamo L. Pain and Functional Scores in Patients Affected by Knee OA after Treatment with Pulsed Electromagnetic and Magnetic Fields: A Meta-Analysis. Cartilage 2021;13:1749S-60S. [PMID: 32508140 DOI: 10.1177/1947603520931168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Luongo L, Guida F, Maione S, Jacobson KA, Salvemini D. Adenosine Metabotropic Receptors in Chronic Pain Management. Front Pharmacol 2021;12:651038. [PMID: 33935761 DOI: 10.3389/fphar.2021.651038] [Reference Citation Analysis]
16 Gorain B, Choudhury H, Yee GS, Bhattamisra SK. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers. CPD 2019;25:2828-41. [DOI: 10.2174/1381612825666190716102037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Santiago AR, Madeira MH, Boia R, Aires ID, Rodrigues-Neves AC, Santos PF, Ambrósio AF. Keep an eye on adenosine: Its role in retinal inflammation. Pharmacol Ther 2020;210:107513. [PMID: 32109489 DOI: 10.1016/j.pharmthera.2020.107513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
18 Fatoki T, Awofisayo O, Faleye B. Cipargamin could inhibit human adenosine receptor A3 with higher binding affinity than Plasmodium falciparum P-type ATPase 4: An In silico study. Acta fac medic Naissensis 2022;39:23-36. [DOI: 10.5937/afmnai39-31499] [Reference Citation Analysis]
19 Gao ZG, Jacobson KA. Purinergic Signaling in Mast Cell Degranulation and Asthma. Front Pharmacol 2017;8:947. [PMID: 29311944 DOI: 10.3389/fphar.2017.00947] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
20 Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells 2020;9:E785. [PMID: 32213945 DOI: 10.3390/cells9030785] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
21 Ferreira-Silva J, Aires ID, Boia R, Ambrósio AF, Santiago AR. Activation of Adenosine A3 Receptor Inhibits Microglia Reactivity Elicited by Elevated Pressure. Int J Mol Sci 2020;21:E7218. [PMID: 33007835 DOI: 10.3390/ijms21197218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R. An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis. Biologics 2020;14:53-75. [PMID: 32903867 DOI: 10.2147/BTT.S260754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cheng P, Zhang J, Chu Z, Liu W, Lin H, Wu Y, Zhu J. A3 adenosine receptor agonist IB-MECA reverses chronic cerebral ischemia-induced inhibitory avoidance memory deficit. European Journal of Pharmacology 2022;921:174874. [DOI: 10.1016/j.ejphar.2022.174874] [Reference Citation Analysis]
24 Pineux F, Federico S, Klotz KN, Kachler S, Michiels C, Sturlese M, Prato M, Spalluto G, Moro S, Bonifazi D. Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A3 Adenosine Receptor. ChemMedChem 2020;15:1909-20. [PMID: 32706529 DOI: 10.1002/cmdc.202000466] [Reference Citation Analysis]
25 López-Cano M, Filgaira I, Nolen EG, Cabré G, Hernando J, Tosh DK, Jacobson KA, Soler C, Ciruela F. Optical control of adenosine A3 receptor function in psoriasis. Pharmacol Res 2021;170:105731. [PMID: 34157422 DOI: 10.1016/j.phrs.2021.105731] [Reference Citation Analysis]
26 IJzerman AP, Jacobson KA, Müller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacol Rev 2022;74:340-72. [PMID: 35302044 DOI: 10.1124/pharmrev.121.000445] [Reference Citation Analysis]
27 Wang S, Gao S, Zhou D, Qian X, Luan J, Lv X. The role of the CD39-CD73-adenosine pathway in liver disease. J Cell Physiol 2021;236:851-62. [PMID: 32648591 DOI: 10.1002/jcp.29932] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Garcia-Garcia L, Olle L, Martin M, Roca-Ferrer J, Muñoz-Cano R. Adenosine Signaling in Mast Cells and Allergic Diseases. Int J Mol Sci 2021;22:5203. [PMID: 34068999 DOI: 10.3390/ijms22105203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Suresh RR, Jain S, Chen Z, Tosh DK, Ma Y, Podszun MC, Rotman Y, Salvemini D, Jacobson KA. Design and in vivo activity of A3 adenosine receptor agonist prodrugs. Purinergic Signal 2020;16:367-77. [PMID: 32720036 DOI: 10.1007/s11302-020-09715-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Storme J, Tosh DK, Gao ZG, Jacobson KA, Stove CP. Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives. Biochem Pharmacol 2018;158:103-13. [PMID: 30292756 DOI: 10.1016/j.bcp.2018.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Bouzo-Lorenzo M, Stoddart LA, Xia L, IJzerman AP, Heitman LH, Briddon SJ, Hill SJ. A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A3 receptor. Purinergic Signal 2019;15:139-53. [PMID: 30919204 DOI: 10.1007/s11302-019-09650-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
32 Jain AR, Robinson AS. Functional Expression of Adenosine A3 Receptor in Yeast Utilizing a Chimera with the A2AR C-Terminus. Int J Mol Sci 2020;21:E4547. [PMID: 32604732 DOI: 10.3390/ijms21124547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Patinha D, Abreu C, Carvalho C, Cunha OM, Mota M, Afonso J, Sousa T, Albino-Teixeira A, Diniz C, Morato M. Adenosine A2A and A3 Receptors as Targets for the Treatment of Hypertensive-Diabetic Nephropathy. Biomedicines 2020;8:E529. [PMID: 33238361 DOI: 10.3390/biomedicines8110529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Xia L, Kyrizaki A, Tosh DK, van Duijl TT, Roorda JC, Jacobson KA, IJzerman AP, Heitman LH. A binding kinetics study of human adenosine A3 receptor agonists. Biochem Pharmacol 2018;153:248-59. [PMID: 29305857 DOI: 10.1016/j.bcp.2017.12.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Chimenti MS, Triggianese P, De Martino E, Conigliaro P, Fonti GL, Sunzini F, Caso F, Perricone C, Costa L, Perricone R. An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol. 2019;15:823-836. [PMID: 31177868 DOI: 10.1080/1744666x.2019.1627876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
36 Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA. Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists. Medchemcomm 2018;9:1920-32. [PMID: 30568760 DOI: 10.1039/c8md00317c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ciancetta A, Rubio P, Lieberman DI, Jacobson KA. A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states. J Comput Aided Mol Des 2019;33:983-96. [PMID: 31758354 DOI: 10.1007/s10822-019-00246-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ren TH, Lv MM, An XM, Leung WK, Seto WK. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling. J Dig Dis 2020;21:38-45. [PMID: 31714673 DOI: 10.1111/1751-2980.12831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sebastião AM, Rei N, Ribeiro JA. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front Pharmacol 2018;9:267. [PMID: 29713276 DOI: 10.3389/fphar.2018.00267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
40 Jacobson KA, Giancotti LA, Lauro F, Mufti F, Salvemini D. Treatment of chronic neuropathic pain: purine receptor modulation. Pain 2020;161:1425-41. [PMID: 32187120 DOI: 10.1097/j.pain.0000000000001857] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
41 Antonioli L, Lucarini E, Lambertucci C, Fornai M, Pellegrini C, Benvenuti L, Di Cesare Mannelli L, Spinaci A, Marucci G, Blandizzi C, Ghelardini C, Volpini R, Dal Ben D. The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. Cells 2020;9:E1509. [PMID: 32575844 DOI: 10.3390/cells9061509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Garrido W, Jara C, Torres A, Suarez R, Cappelli C, Oyarzún C, Quezada C, San Martín R. Blockade of the Adenosine A3 Receptor Attenuates Caspase 1 Activation in Renal Tubule Epithelial Cells and Decreases Interleukins IL-1β and IL-18 in Diabetic Rats. Int J Mol Sci 2019;20:E4531. [PMID: 31540220 DOI: 10.3390/ijms20184531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
43 Jacobson KA, Tosh DK, Gao Z, Yu J, Suresh RR, Rao H, Romagnoli R, Baraldi PG, Aghazadeh Tabrizi M. Medicinal Chemistry of the A3 Adenosine Receptor. In: Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F, editors. The Adenosine Receptors. Cham: Springer International Publishing; 2018. pp. 169-98. [DOI: 10.1007/978-3-319-90808-3_7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D, Varano F, Merighi S, Borea PA, Varani K. Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. Front Pharmacol 2017;8:888. [PMID: 29249971 DOI: 10.3389/fphar.2017.00888] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
45 Dal Ben D, Antonioli L, Lambertucci C, Fornai M, Blandizzi C, Volpini R. Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. Front Pharmacol 2018;9:212. [PMID: 29593540 DOI: 10.3389/fphar.2018.00212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
46 Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol 2021;14:78. [PMID: 33980266 DOI: 10.1186/s13045-021-01085-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Li J, Hong X, Li G, Conti PS, Zhang X, Chen K. PET Imaging of Adenosine Receptors in Diseases. Curr Top Med Chem 2019;19:1445-63. [PMID: 31284861 DOI: 10.2174/1568026619666190708163407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Trapero C, Martín-Satué M. Purinergic Signaling in Endometriosis-Associated Pain. Int J Mol Sci 2020;21:E8512. [PMID: 33198179 DOI: 10.3390/ijms21228512] [Reference Citation Analysis]
49 Pottie E, Tosh DK, Gao ZG, Jacobson KA, Stove CP. Assessment of biased agonism at the A3 adenosine receptor using β-arrestin and miniGαi recruitment assays. Biochem Pharmacol 2020;177:113934. [PMID: 32224136 DOI: 10.1016/j.bcp.2020.113934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
50 Mailavaram RP, Al-attraqchi OH, Kar S, Ghosh S. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents. CPD 2019;25:2772-87. [DOI: 10.2174/1381612825666190716114056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Buccioni M, Dal Ben D, Lambertucci C, Martí Navia A, Ricciutelli M, Spinaci A, Volpini R, Marucci G. New sensible method to quantize the intestinal absorption of receptor ligands. Bioorg Med Chem 2019;27:3328-33. [PMID: 31230970 DOI: 10.1016/j.bmc.2019.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Areias F, Correia C, Rocha A, Brea J, Castro M, Loza MI, Proença MF, Carvalho MA. 2-Aryladenine derivatives as a potent scaffold for A1, A3 and dual A1/A3 adenosine receptor antagonists: Synthesis and structure-activity relationships. Bioorg Med Chem 2019;27:3551-8. [PMID: 31280999 DOI: 10.1016/j.bmc.2019.06.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Cioato SG, Medeiros LF, Lopes BC, de Souza A, Medeiros HR, Assumpção JAF, Caumo W, Roesler R, Torres ILS. Antinociceptive and neurochemical effects of a single dose of IB-MECA in chronic pain rat models. Purinergic Signal 2020;16:573-84. [PMID: 33161497 DOI: 10.1007/s11302-020-09751-w] [Reference Citation Analysis]
54 Shakya AK, Naik RR, Almasri IM, Kaur A. Role and Function of Adenosine and its Receptors in Inflammation, Neuroinflammation, IBS, Autoimmune Inflammatory Disorders, Rheumatoid Arthritis and Psoriasis. Curr Pharm Des 2019;25:2875-91. [PMID: 31333103 DOI: 10.2174/1381612825666190716145206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Suresh RR, Poe RB, Lin B, Lv K, Campbell RG, Gao ZG, Liston TE, Toti KS, Jacobson KA. Convergent synthesis of 2-thioether-substituted (N)-methanocarba-adenosines as purine receptor agonists. RSC Adv 2021;11:27369-80. [PMID: 35480676 DOI: 10.1039/d1ra05096f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Rombo DM, Ribeiro JA, Sebastião AM. Role of Adenosine Receptors in Epileptic Seizures. In: Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F, editors. The Adenosine Receptors. Cham: Springer International Publishing; 2018. pp. 309-50. [DOI: 10.1007/978-3-319-90808-3_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Sahin Z, Biltekin SN, Yurttas L, Berk B, Özhan Y, Sipahi H, Gao ZG, Jacobson KA, Demirayak Ş. Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition. Eur J Med Chem 2021;212:113125. [PMID: 33422981 DOI: 10.1016/j.ejmech.2020.113125] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Singh AK, Mahalingam R, Squillace S, Jacobson KA, Tosh DK, Dharmaraj S, Farr SA, Kavelaars A, Salvemini D, Heijnen CJ. Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice. Acta Neuropathol Commun 2022;10:11. [PMID: 35093182 DOI: 10.1186/s40478-022-01315-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Barresi E, Martini C, Da Settimo F, Greco G, Taliani S, Giacomelli C, Trincavelli ML. Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications. Front Pharmacol 2021;12:652121. [PMID: 33841166 DOI: 10.3389/fphar.2021.652121] [Reference Citation Analysis]
60 Ballesteros-Yáñez I, Castillo CA, Merighi S, Gessi S. The Role of Adenosine Receptors in Psychostimulant Addiction. Front Pharmacol 2017;8:985. [PMID: 29375384 DOI: 10.3389/fphar.2017.00985] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
61 Wang Y, He M, Li X, Chai J, Jiang Q, Peng C, He G, Huang W. Design, Synthesis, and Biological Evaluation of Pyrano[2,3-c]-pyrazole-Based RalA Inhibitors Against Hepatocellular Carcinoma. Front Chem 2021;9:700956. [PMID: 34869198 DOI: 10.3389/fchem.2021.700956] [Reference Citation Analysis]
62 Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. J Infect Dis 2020;221:1598-606. [PMID: 31282542 DOI: 10.1093/infdis/jiz344] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
63 Tosh DK, Salmaso V, Campbell RG, Rao H, Bitant A, Pottie E, Stove CP, Liu N, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. Eur J Med Chem 2022;228:113983. [PMID: 34844790 DOI: 10.1016/j.ejmech.2021.113983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Chimenti MS, Perricone C, Conigliaro P, Triggianese P, D'Antonio A, de Martino E, Fonti GL, Caso F, Costa L, Perricone R. Tackling the autoimmune side in Spondyloarthritis: A systematic review. Autoimmun Rev 2020;19:102648. [PMID: 32801035 DOI: 10.1016/j.autrev.2020.102648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Spinozzi E, Baldassarri C, Acquaticci L, Del Bello F, Grifantini M, Cappellacci L, Riccardo P. Adenosine receptors as promising targets for the management of ocular diseases. Med Chem Res 2021;:1-18. [PMID: 33519168 DOI: 10.1007/s00044-021-02704-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Jacobson KA, Tosh DK, Jain S, Gao ZG. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci 2019;13:124. [PMID: 30983976 DOI: 10.3389/fncel.2019.00124] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 22.7] [Reference Citation Analysis]
67 Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao ZG, Auchampach JA, Jacobson KA. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A3 Receptor Agonists. ACS Med Chem Lett 2020;11:1935-41. [PMID: 33062176 DOI: 10.1021/acsmedchemlett.9b00637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
68 Merighi S, Gessi S, Borea PA. Adenosine Receptors: Structure, Distribution, and Signal Transduction. In: Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F, editors. The Adenosine Receptors. Cham: Springer International Publishing; 2018. pp. 33-57. [DOI: 10.1007/978-3-319-90808-3_3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
69 Hu S, Guo P, Wang Z, Zhou Z, Wang R, Zhang M, Tao J, Tai Y, Zhou W, Wei W, Wang Q. Down-regulation of A3AR signaling by IL-6-induced GRK2 activation contributes to Th17 cell differentiation. Exp Cell Res 2021;399:112482. [PMID: 33434531 DOI: 10.1016/j.yexcr.2021.112482] [Reference Citation Analysis]
70 Gratal P, Lamuedra A, Medina JP, Bermejo-Álvarez I, Largo R, Herrero-Beaumont G, Mediero A. Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. Front Med (Lausanne) 2020;7:506. [PMID: 32984382 DOI: 10.3389/fmed.2020.00506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lucarini E, Coppi E, Micheli L, Parisio C, Vona A, Cherchi F, Pugliese AM, Pedata F, Failli P, Palomino S, Wahl J, Largent-Milnes TM, Vanderah TW, Tosh DK, Jacobson KA, Salvemini D, Ghelardini C, Di Cesare Mannelli L. Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels. Pain 2020;161:2179-90. [PMID: 32379223 DOI: 10.1097/j.pain.0000000000001905] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
72 Magni G, Ceruti S. The role of adenosine and P2Y receptors expressed by multiple cell types in pain transmission. Brain Res Bull 2019;151:132-43. [PMID: 30797817 DOI: 10.1016/j.brainresbull.2019.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
73 Silva-Vilches C, Ring S, Mahnke K. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity. Front Immunol 2018;9:2581. [PMID: 30473700 DOI: 10.3389/fimmu.2018.02581] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
74 Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F. Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. J Exp Pharmacol 2020;12:487-502. [PMID: 33235521 DOI: 10.2147/JEP.S265633] [Reference Citation Analysis]
75 Farr SA, Cuzzocrea S, Esposito E, Campolo M, Niehoff ML, Doyle TM, Salvemini D. Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury. J Neuroinflammation 2020;17:339. [PMID: 33183330 DOI: 10.1186/s12974-020-02009-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
76 Ciruela F, Jacobson KA. Optical Control of Adenosine A3 Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis? Front Immunol 2022;13:904762. [DOI: 10.3389/fimmu.2022.904762] [Reference Citation Analysis]
77 Thakur V, Mahajan R. Novel Therapeutic Target(s) for Psoriatic Disease. Front Med 2022;9:712313. [DOI: 10.3389/fmed.2022.712313] [Reference Citation Analysis]